肾细胞癌的未来方向：2011 年及以后。
Future directions in renal cell carcinoma: 2011 and beyond.
机构信息
Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.
出版信息
Hematol Oncol Clin North Am. 2011 Aug;25(4):917-35. doi: 10.1016/j.hoc.2011.05.001.
Abstract
Emerging from a largely cytokine-based era, the last several years have witnessed a dramatic change in the therapeutic landscape of renal cancer. Molecularly targeted and antiangiogenic agents now form the backbone of most therapeutic strategies for patients with advanced renal cell carcinoma (RCC). Although the next few years may not see such broad paradigm shifts, there remains significant room for improvement in the care of patients with RCC. This review discusses challenges that face physicians and researchers as well as innovations that may contribute to improving the therapeutic outcomes for patients with RCC.
摘要
从以细胞因子为基础的时代中脱颖而出，过去几年见证了肾癌治疗领域的巨大变化。分子靶向药物和抗血管生成药物现在构成了晚期肾细胞癌（RCC）患者大多数治疗策略的基础。尽管未来几年可能不会出现如此广泛的范式转变，但在 RCC 患者的治疗中仍有很大的改进空间。本文讨论了医生和研究人员面临的挑战，以及可能有助于改善 RCC 患者治疗效果的创新。
相似文献
1
Future directions in renal cell carcinoma: 2011 and beyond.肾细胞癌的未来方向：2011 年及以后。
Hematol Oncol Clin North Am. 2011 Aug;25(4):917-35. doi: 10.1016/j.hoc.2011.05.001.
2
Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.肾细胞癌的临床和分子预后因素：目前我们所了解的。
Hematol Oncol Clin North Am. 2011 Aug;25(4):871-91. doi: 10.1016/j.hoc.2011.04.003.
3
Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development.超越VEGF/mTOR抑制作用：肾细胞癌药物研发的新靶点
Curr Clin Pharmacol. 2011 Aug;6(3):199-206. doi: 10.2174/157488411797189389.
4
Novel molecular targets for the therapy of renal cell carcinoma.肾细胞癌治疗的新型分子靶点
Discov Med. 2012 Jun;13(73):461-71.
5
Toxicities of targeted agents in advanced renal cell carcinoma.晚期肾细胞癌中靶向药物的毒性
Curr Clin Pharmacol. 2011 Aug;6(3):181-8. doi: 10.2174/157488411797189442.
6
Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.初步临床证据表明，麦角酰胺通过抑制 MNK/eIF4E 增强了肾细胞癌对血管生成 TKI 和 mTOR 抑制剂的反应。
Biochem Biophys Res Commun. 2020 Sep 10;530(1):142-148. doi: 10.1016/j.bbrc.2020.06.133. Epub 2020 Jul 30.
7
Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm.转移性肾细胞癌的新型治疗方法：超越 VEGF/mTOR 信号通路的努力。
Mol Cancer Ther. 2012 Mar;11(3):526-37. doi: 10.1158/1535-7163.MCT-11-0806. Epub 2012 Feb 17.
8
Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review.肾细胞癌中的分子靶点与血管生成：多靶点方法综述
Curr Drug Targets. 2017;18(10):1204-1213. doi: 10.2174/1389450117666160502152518.
9
Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.晚期肾细胞癌的抗血管生成治疗：治疗相关毒性的管理。
Invest New Drugs. 2012 Oct;30(5):2066-79. doi: 10.1007/s10637-012-9796-8. Epub 2012 Feb 12.
10
Protein kinase inhibitors in renal cell carcinoma.肾细胞癌中的蛋白激酶抑制剂
Expert Opin Pharmacother. 2014 Feb;15(3):337-51. doi: 10.1517/14656566.2014.869210. Epub 2013 Dec 16.
引用本文的文献
1
Targeted Therapy for Metastatic Renal Carcinoma: an Update.转移性肾癌的靶向治疗：最新进展
J Kidney Cancer VHL. 2014 Oct 21;1(6):63-73. doi: 10.15586/jkcvhl.2014.14. eCollection 2014.
2
Sunitinib resistance in renal cell carcinoma.肾细胞癌中的舒尼替尼耐药性。
J Kidney Cancer VHL. 2014 Apr 22;1(1):1-11. doi: 10.15586/jkcvhl.2014.7. eCollection 2014.
3
A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.来那度胺联合舒尼替尼治疗晚期或转移性肾细胞癌的I/II期研究。
Ann Oncol. 2014 Sep;25(9):1794-1799. doi: 10.1093/annonc/mdu212. Epub 2014 Jun 8.
4
Englerin a selectively induces necrosis in human renal cancer cells.恩格勒因a选择性地诱导人肾癌细胞坏死。
PLoS One. 2012;7(10):e48032. doi: 10.1371/journal.pone.0048032. Epub 2012 Oct 22.
5
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.高剂量间歇性索拉非尼在肾细胞癌中的疗效优于常规连续剂量。
J Transl Med. 2011 Dec 21;9:220. doi: 10.1186/1479-5876-9-220.
本文引用的文献
1
Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.在一项评估肾细胞癌患者抗肿瘤活性和安全性的 II 期随机停药试验中，替沃扎尼（AV-951）的表现。
J Clin Oncol. 2012 May 10;30(14):1678-85. doi: 10.1200/JCO.2011.35.3524. Epub 2012 Apr 9.
2
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.原发性抗血管内皮生长因子 (VEGF) 治疗抵抗转移性肾细胞癌：临床特征、危险因素和后续治疗。
Ann Oncol. 2012 Jun;23(6):1549-55. doi: 10.1093/annonc/mdr533. Epub 2011 Nov 5.
3
Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib.成纤维细胞生长因子 2 调节内皮细胞对舒尼替尼的敏感性。
Oncogene. 2011 Mar 10;30(10):1183-93. doi: 10.1038/onc.2010.503. Epub 2010 Nov 8.
4
HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.HGF/c-Met 作为索坦耐药肿瘤的一种替代血管生成途径。
Cancer Res. 2010 Dec 15;70(24):10090-100. doi: 10.1158/0008-5472.CAN-10-0489. Epub 2010 Oct 15.
5
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.NK 细胞 KIR 受体、其配体和 Fcγ 受体的基因型在神经母细胞瘤患者对 Hu14.18-IL2 免疫治疗反应中的作用。
Cancer Res. 2010 Dec 1;70(23):9554-61. doi: 10.1158/0008-5472.CAN-10-2211. Epub 2010 Oct 8.
6
Biomarkers: hypertension following anti-angiogenesis therapy.生物标志物：抗血管生成治疗后的高血压
Clin Adv Hematol Oncol. 2010 Jun;8(6):415-6.
7
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy.黑色素瘤相关基因特征与临床活性相关：解锁癌症免疫治疗的潜在线索。
Cancer J. 2010 Jul-Aug;16(4):399-403. doi: 10.1097/PPO.0b013e3181eacbd8.
8
Cancer statistics, 2010.癌症统计数据，2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
9
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.新型双重 PI3-激酶/mTOR 抑制剂 NVP-BEZ235 对比雷帕霉素治疗肾细胞癌的疗效。
Clin Cancer Res. 2010 Jul 15;16(14):3628-38. doi: 10.1158/1078-0432.CCR-09-3022. Epub 2010 Jul 6.
10
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.贝伐珠单抗联合依维莫司治疗晚期肾细胞癌的 II 期临床试验。
J Clin Oncol. 2010 May 1;28(13):2131-6. doi: 10.1200/JCO.2009.26.3152. Epub 2010 Apr 5.
Zotero 插件